52/100BDR Horton stock forecast 2027–2031
Analysts' average 12-month price target for DR Horton is 157.17, 3.2% above the current price of 152.26. Their targets range from 130.00 to 182.00.
Of the 16 firms that rated DR Horton in the past 12 months, 4 rate it buy or strong buy, 10 hold and 2 sell or strong sell (each firm at its latest rating): a Hold consensus.
Analysts' 1-year price targets range from 130.00 to 182.00, with an average of 157.17.
| Strong buy | 0 | |
| Buy | 4 | |
| Hold | 10 | |
| Sell | 2 | |
| Strong sell | 0 |
12-month price target
| Highest target | 182.00 |
| Average target | 157.17 |
| Lowest target | 130.00 |
| Current price | 152.26 |
DR Horton price target history
Have analysts recently raised or lowered their DR Horton price target and rating?
How analysts rate DR Horton, month by month
4 of 16 firms rate it buy now, against 5 of 13 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
DR Horton analyst upgrades, downgrades and price targets
The latest rating change came on 3 November 2026, when Raymond James downgraded DR Horton from Market Perform to Underperform. The most recent new target came from Wells Fargo on 16 October 2026: 140.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 3 Nov 2026 | Raymond James | Downgraded · Market Perform → Underperform | — | — | — |
| 16 Oct 2026 | Wells Fargo Sam Reid | Reiterated · Equal Weight | 145.00 → 140.00 | -3.4% | 139.55 |
| 12 Oct 2026 | Goldman Sachs Susan Maklari | — | 190.00 → 182.00 | -4.2% | 134.88 |
| 6 Oct 2026 | Barclays | Reiterated · Equal Weight | 141.00 → 130.00 | -7.8% | 133.23 |
| 1 Oct 2026 | Morgan Stanley | — | 151.00 | — | 136.65 |
| 25 Sept 2026 | Evercore ISI | Reiterated · In Line | 169.00 → 166.00 | -1.8% | 140.35 |
| 22 Sept 2026 | BTIG Ryan Gilbert | — | 184.00 → 174.00 | -5.4% | 139.25 |
| 11 Sept 2026 | Wells Fargo | Reiterated · Equal Weight | 158.00 → 145.00 | -8.2% | 135.57 |
| 22 Jul 2026 | BTIG | — | 182.00 → 184.00 | +1.1% | 143.52 |
| 14 Jul 2026 | Barclays | Reiterated · Equal Weight | 129.00 → 141.00 | +9.3% | 148.85 |
| 7 Jul 2026 | Zelman & Assoc | Upgraded · Neutral → Outperform | — | — | — |
| 21 Apr 2026 | Goldman Sachs Susan Maklari | — | 195.00 → 190.00 | -2.6% | 162.20 |
| 16 Apr 2026 | Truist Financial | Reiterated · Hold | 155.00 → 140.00 | -9.7% | 144.51 |
| 7 Apr 2026 | Seaport Global | Downgraded · Buy → Neutral | — | — | — |
| 3 Mar 2026 | Truist Financial Jonathan Bettenhausen | — | 155.00 | — | 152.61 |
| 27 Jan 2026 | UBS | — | 193.00 → 163.00 | -15.5% | 149.10 |
| 23 Jan 2026 | Argus Research Chris Graja | Reiterated · Buy | 185.00 | — | 154.55 |
| 21 Jan 2026 | BTIG | — | 186.00 → 182.00 | -2.2% | 156.71 |
| 21 Jan 2026 | Barclays | Reiterated · Equal Weight | 132.00 → 129.00 | -2.3% | 153.19 |
| 21 Jan 2026 | Wells Fargo | — | 155.00 → 158.00 | +1.9% | 153.19 |
| 20 Jan 2026 | UBS John Lovallo | — | 191.00 → 193.00 | +1.0% | 153.19 |
| 13 Jan 2026 | Goldman Sachs | — | 195.00 | — | 159.71 |
| 7 Jan 2026 | Citizens | Downgraded · Market Outperform → Market Perform | — | — | — |
| 6 Jan 2026 | UBS | Reiterated · Buy | 195.00 → 191.00 | -2.1% | 146.48 |
| 6 Jan 2026 | Wells Fargo Sam Reid | Downgraded · Overweight → Equal Weight | 180.00 → 155.00 | -13.9% | 146.48 |
| 8 Dec 2025 | Barclays Matthew Bouley | Reiterated · Equal Weight | 132.00 | — | 158.62 |
| 8 Dec 2025 | Wells Fargo Sam Reid | Reiterated · Overweight | 180.00 | — | 158.62 |
| 1 Dec 2025 | BTIG | — | 150.00 → 186.00 | +24.0% | 157.37 |
DR Horton EPS and revenue estimates
Analysts expect DR Horton's EPS to grow 5.8% a year until 2029. Over the last 5 years it fell 2.4% a year, and over the last 3 years it fell 9.9%.
Analysts expect DR Horton's revenue to fall 0.6% a year until 2028. Over the last 5 years it grew 3.5% a year, and over the last 3 years it fell 2.3%.
Revenue
EPS
Does DR Horton beat earnings estimates?
On average, analysts' EPS estimate was 7.7% off the result, either way, and their revenue estimate 4.1%, over the last 12 quarters.
- EPS beats
- 90 / 134
- Revenue beats
- 89 / 119
- Average EPS surprise, last 12
- +3.0%
- Since
- February 1993
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q4 FY2026 | 29 Oct 2026 | 3.01 | 2.67 | -11.3% | 9.07B | 9.37B | +3.3% |
| Q3 FY2026 | 21 Jul 2026 | 3.02 | 3.20 | +6.0% | 9.10B | 9.23B | +1.4% |
| Q2 FY2026 | 21 Apr 2026 | 2.15 | 2.24 | +4.2% | 7.55B | 7.56B | +0.1% |
| Q1 FY2026 | 20 Jan 2026 | 1.93 | 2.03 | +5.2% | 6.59B | 6.89B | +4.6% |
| Q4 FY2025 | 28 Oct 2025 | 3.27 | 3.04 | -7.0% | 9.41B | 9.68B | +2.8% |
| Q3 FY2025 | 22 Jul 2025 | 2.94 | 3.36 | +14.3% | 8.77B | 9.23B | +5.1% |
| Q2 FY2025 | 17 Apr 2025 | 2.62 | 2.58 | -1.5% | 8.03B | 7.73B | -3.7% |
| Q1 FY2025 | 21 Jan 2025 | 2.37 | 2.61 | +10.1% | 7.01B | 7.61B | +8.5% |
| Q4 FY2024 | 29 Oct 2024 | 4.17 | 3.92 | -6.0% | 10.22B | 10.00B | -2.1% |
| Q3 FY2024 | 18 Jul 2024 | 3.75 | 4.10 | +9.3% | 9.61B | 9.97B | +3.7% |
| Q2 FY2024 | 18 Apr 2024 | 3.06 | 3.52 | +15.0% | 8.15B | 9.11B | +11.8% |
| Q1 FY2024 | 23 Jan 2024 | 2.88 | 2.82 | -2.1% | 7.60B | 7.73B | +1.7% |
DR Horton stock price 2027–2031: scenarios
If DR Horton's earnings keep growing at the 5.7% a year analysts expect to FY2029, it would earn about 13.39 a share in FY2031. At the P/E it has traded at over the last five years (4.0 to 14.6) that is 54.15 to 195.25 a share, or 141.99 at its average P/E of 10.6. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2027 | 8.57 | 34.67 | 90.90 | 124.99 |
| FY2028 | 10.49 | 42.44 | 111.27 | 153.00 |
| FY2029 | 11.98 | 48.46 | 127.06 | 174.71 |
| FY2030 (extrapolated) | 12.66 | 51.23 | 134.32 | 184.69 |
| FY2031 (extrapolated) | 13.39 | 54.15 | 141.99 | 195.25 |
Each year's EPS is the analysts' consensus to FY2029; the years after continue its 5.7% a year. Bear, base and bull apply the lowest, average and highest P/E of the last five fiscal year ends (4.0, 10.6, 14.6).
Is DR Horton stock undervalued or overvalued?
DR Horton's P/E of 15.0 is near the top of its 5-year range (4.3 to 15.6, median 10.3). It is within 5% of its 5-year high. Analysts do not expect faster growth than in recent years, so it is expensive compared with its own history. At its usual P/E (10.3 × EPS of 10.14), DR Horton's fair value is 104.64; the price, 152.26, is 45.5% above it. Its forward P/E, on the consensus for FY2027, is 17.8.
Fair value is the usual (median) P/E of the last five years times the earnings per share of the last twelve months; the ends of the bar are the same earnings at its lowest and highest P/E of those years (4.3 and 15.6). The price against its P/E range
- Price to earnings ratio (TTM)
- 15.02
- Five-year median P/E
- 10.32
- Five-year P/E range
- 4.3 – 15.6
- Forward P/E (FY2027)
- 17.77
- PEG ratio
- 2.63
- To the average target
- +3.2%
Most undervalued US stocks
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 99.090 | 195.10146Price 99.09244 | +96.9% | |
| 186.680 | 359.93270Price 186.68450 | +92.8% | |
| 213.670 | 405.66304Price 213.67507 | +89.9% | |
| 161.160 | 305.51157Price 161.16396 | +89.6% | |
| 42.225 | 79.0244Price 42.23157 | +87.1% | |
| 160.650 | 299.85225Price 160.65375 | +86.6% | |
| 108.445 | 201.41108Price 108.45248 | +85.7% |
Furthest below the fair value on each stock's page, updated every day.